{"id":66914,"date":"2026-06-01T13:33:35","date_gmt":"2026-06-01T05:33:35","guid":{"rendered":"https:\/\/flcube.com\/?p=66914"},"modified":"2026-06-01T13:33:36","modified_gmt":"2026-06-01T05:33:36","slug":"fda-proposes-streamlined-animal-testing-requirements-for-oncology-drugs-to-accelerate-development-timeline","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=66914","title":{"rendered":"FDA Proposes Streamlined Animal Testing Requirements for Oncology Drugs to Accelerate Development Timeline"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\">The <strong>U.S. Food and Drug Administration (FDA)<\/strong> released draft guidance aimed at <strong>reducing unnecessary animal testing<\/strong> in nonclinical safety assessments for certain cancer drugs, potentially shortening the current <strong>10\u201312 year drug development timeline<\/strong>. The document, titled &#8220;<strong>Oncology Pharmaceuticals: Streamlined Nonclinical Safety Studies for Biologics and Conjugated Products<\/strong>,&#8221; outlines specific scenarios where traditional animal studies may be eliminated or modified without compromising patient safety.<\/p>\n\n\n\n<h2 id=\"h-regulatory-framework\" class=\"wp-block-heading\">Regulatory Framework<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Agency<\/strong><\/td><td>FDA (United States)<\/td><\/tr><tr><td><strong>Document Type<\/strong><\/td><td>Draft Guidance (Open for Public Comment)<\/td><\/tr><tr><td><strong>Focus Area<\/strong><\/td><td>Nonclinical Safety Studies for Oncology Pharmaceuticals<\/td><\/tr><tr><td><strong>Target Products<\/strong><\/td><td>Biologics and Conjugated Products for Cancer Treatment<\/td><\/tr><tr><td><strong>Release Date<\/strong><\/td><td>29 May 2026<\/td><\/tr><tr><td><strong>Next Steps<\/strong><\/td><td>Public comment period before finalization<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-key-recommendations\" class=\"wp-block-heading\">Key Recommendations<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Elimination Criteria:<\/strong> Animal testing may be unnecessary when there is <strong>no binding or pharmacologic activity<\/strong> in non-target species\u2014a common scenario with highly specific oncology agents.<\/li>\n\n\n\n<li><strong>Species Reduction:<\/strong> In some cases, toxicology studies would be required only in <strong>rodent species<\/strong> rather than both rodents and non-rodents.<\/li>\n\n\n\n<li><strong>Study Replacement:<\/strong> <strong>Three-month non-human primate studies<\/strong> may be replaced with a comprehensive <strong>weight-of-evidence risk assessment<\/strong> that synthesizes all available data.<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-strategic-rationale\" class=\"wp-block-heading\">Strategic Rationale<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">The FDA&#8217;s initiative addresses a critical bottleneck in oncology drug development. Many modern cancer therapies\u2014particularly biologics and antibody-drug conjugates\u2014are designed with such precise molecular targeting that they have minimal interaction with non-human biological systems. Traditional toxicology requirements, developed decades ago for small-molecule drugs with broader biological effects, often yield little relevant safety information for these targeted agents.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">&#8220;This guidance reflects our commitment to modernizing regulatory science while maintaining rigorous safety standards,&#8221; said an FDA spokesperson. &#8220;By eliminating redundant testing requirements that don&#8217;t provide meaningful human safety data, we can accelerate the delivery of potentially life-saving treatments to patients who need them.&#8221;<\/p>\n\n\n\n<h2 id=\"h-industry-impact-amp-outlook\" class=\"wp-block-heading\">Industry Impact &amp; Outlook<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Development Cost Reduction:<\/strong> Eliminating unnecessary primate studies could save developers <strong>$2\u20135 million per program<\/strong> and reduce timelines by <strong>3\u20136 months<\/strong>.<\/li>\n\n\n\n<li><strong>Innovation Acceleration:<\/strong> Streamlined requirements may encourage investment in novel oncology platforms that previously faced disproportionate regulatory burdens.<\/li>\n\n\n\n<li><strong>Global Harmonization:<\/strong> The FDA&#8217;s approach aligns with similar initiatives by the <strong>European Medicines Agency (EMA)<\/strong> and <strong>Japan&#8217;s PMDA<\/strong>, potentially creating more consistent international standards.<\/li>\n\n\n\n<li><strong>Ethical Considerations:<\/strong> The guidance supports the &#8220;<strong>3Rs principle<\/strong>&#8221; (Replacement, Reduction, Refinement) in animal research, responding to growing ethical concerns about primate use in drug development.<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward-looking statements regarding regulatory policy changes and their potential impact on drug development timelines and costs. Actual implementation may vary based on public comments, final guidance language, and industry adoption patterns.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><\/p>\n","protected":false},"excerpt":{"rendered":"<p>The U.S. Food and Drug Administration (FDA) released draft guidance aimed at reducing unnecessary animal&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11,4],"tags":[],"class_list":["post-66914","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","category-policy-regulatory"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v27.7) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>FDA Proposes Streamlined Animal Testing Requirements for Oncology Drugs to Accelerate Development Timeline - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"The U.S. Food and Drug Administration (FDA) released draft guidance aimed at reducing unnecessary animal testing in nonclinical safety assessments for certain cancer drugs, potentially shortening the current 10\u201312 year drug development timeline. The document, titled &quot;Oncology Pharmaceuticals: Streamlined Nonclinical Safety Studies for Biologics and Conjugated Products,&quot; outlines specific scenarios where traditional animal studies may be eliminated or modified without compromising patient safety.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=66914\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"FDA Proposes Streamlined Animal Testing Requirements for Oncology Drugs to Accelerate Development Timeline\" \/>\n<meta property=\"og:description\" content=\"The U.S. Food and Drug Administration (FDA) released draft guidance aimed at reducing unnecessary animal testing in nonclinical safety assessments for certain cancer drugs, potentially shortening the current 10\u201312 year drug development timeline. The document, titled &quot;Oncology Pharmaceuticals: Streamlined Nonclinical Safety Studies for Biologics and Conjugated Products,&quot; outlines specific scenarios where traditional animal studies may be eliminated or modified without compromising patient safety.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=66914\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-06-01T05:33:35+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-06-01T05:33:36+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=66914#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=66914\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"FDA Proposes Streamlined Animal Testing Requirements for Oncology Drugs to Accelerate Development Timeline\",\"datePublished\":\"2026-06-01T05:33:35+00:00\",\"dateModified\":\"2026-06-01T05:33:36+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=66914\"},\"wordCount\":425,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"articleSection\":[\"Company\",\"Drug\",\"Policy \\\/ Regulatory\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=66914#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=66914\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=66914\",\"name\":\"FDA Proposes Streamlined Animal Testing Requirements for Oncology Drugs to Accelerate Development Timeline - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-06-01T05:33:35+00:00\",\"dateModified\":\"2026-06-01T05:33:36+00:00\",\"description\":\"The U.S. Food and Drug Administration (FDA) released draft guidance aimed at reducing unnecessary animal testing in nonclinical safety assessments for certain cancer drugs, potentially shortening the current 10\u201312 year drug development timeline. The document, titled \\\"Oncology Pharmaceuticals: Streamlined Nonclinical Safety Studies for Biologics and Conjugated Products,\\\" outlines specific scenarios where traditional animal studies may be eliminated or modified without compromising patient safety.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=66914#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=66914\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=66914#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"FDA Proposes Streamlined Animal Testing Requirements for Oncology Drugs to Accelerate Development Timeline\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"FDA Proposes Streamlined Animal Testing Requirements for Oncology Drugs to Accelerate Development Timeline - Insight, China&#039;s Pharmaceutical Industry","description":"The U.S. Food and Drug Administration (FDA) released draft guidance aimed at reducing unnecessary animal testing in nonclinical safety assessments for certain cancer drugs, potentially shortening the current 10\u201312 year drug development timeline. The document, titled \"Oncology Pharmaceuticals: Streamlined Nonclinical Safety Studies for Biologics and Conjugated Products,\" outlines specific scenarios where traditional animal studies may be eliminated or modified without compromising patient safety.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=66914","og_locale":"en_US","og_type":"article","og_title":"FDA Proposes Streamlined Animal Testing Requirements for Oncology Drugs to Accelerate Development Timeline","og_description":"The U.S. Food and Drug Administration (FDA) released draft guidance aimed at reducing unnecessary animal testing in nonclinical safety assessments for certain cancer drugs, potentially shortening the current 10\u201312 year drug development timeline. The document, titled \"Oncology Pharmaceuticals: Streamlined Nonclinical Safety Studies for Biologics and Conjugated Products,\" outlines specific scenarios where traditional animal studies may be eliminated or modified without compromising patient safety.","og_url":"https:\/\/flcube.com\/?p=66914","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-06-01T05:33:35+00:00","article_modified_time":"2026-06-01T05:33:36+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=66914#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=66914"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"FDA Proposes Streamlined Animal Testing Requirements for Oncology Drugs to Accelerate Development Timeline","datePublished":"2026-06-01T05:33:35+00:00","dateModified":"2026-06-01T05:33:36+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=66914"},"wordCount":425,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"articleSection":["Company","Drug","Policy \/ Regulatory"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=66914#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=66914","url":"https:\/\/flcube.com\/?p=66914","name":"FDA Proposes Streamlined Animal Testing Requirements for Oncology Drugs to Accelerate Development Timeline - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-06-01T05:33:35+00:00","dateModified":"2026-06-01T05:33:36+00:00","description":"The U.S. Food and Drug Administration (FDA) released draft guidance aimed at reducing unnecessary animal testing in nonclinical safety assessments for certain cancer drugs, potentially shortening the current 10\u201312 year drug development timeline. The document, titled \"Oncology Pharmaceuticals: Streamlined Nonclinical Safety Studies for Biologics and Conjugated Products,\" outlines specific scenarios where traditional animal studies may be eliminated or modified without compromising patient safety.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=66914#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=66914"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=66914#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"FDA Proposes Streamlined Animal Testing Requirements for Oncology Drugs to Accelerate Development Timeline"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/66914","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=66914"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/66914\/revisions"}],"predecessor-version":[{"id":66916,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/66914\/revisions\/66916"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=66914"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=66914"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=66914"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}